It was highlighted that patients with NAFLD showed significantly higher BMI, TCH, LDL-cholesterol, VLDL-cholesterol levels, and ALT and AST activities compared to patients without NAFLD. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.